logo

For the Inventor, By the Inventor

Berlin, Germany

Andrea Hägebarth

This inventor holds 18 USPTO granted patents and 10 published patent applications and 11 EPO patents, primarily in Kinase Inhibitors. Top assignees: Bayer Intellectual Property Gmbh, Bayer Pharma Aktiengesellschaft. Active years: 2014-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrea Hägebarth. Retrieved from https://idiyas.com/inventor/andrea-hägebarth

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 

% Patents Active = 11.1

 

Average Co-Inventor Count = 7.1

ph-index = 3

Forward Citations = 46(Granted Patents)


Company Filing History:

goldMedal10 out of 721 
 
Bayer Intellectual Property Gmbh
 patents
silverMedal10 out of 387 
 
Bayer Pharma Aktiengesellschaft
 patents
where one patent can have more than one assignee

Years Active: 2014-2018

Loading Chart...
Loading Chart...
Areas of Expertise:
PI3K-Inhibitors
Aminoalcohol Compounds
Thienopyrimidines
Imidazopyridazines
Hyper-Proliferative Disorders
Angiogenesis
MKNK-1 Kinase
Akt Kinase
Pyrrolopyrimidinylamino
Pyrimidines
Pyrazolopyrimidines
Indazoles
18 patents (USPTO):Explore Patents
1. 10130633 - Compounds (2018-11-20),
2. 10124007 - Combination of PI3K-inhibitors (2018-11-13),
3. 9902727 - Aminoalcohol substituted 2,3-dihydroimidazo[1,2-C]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis (2018-02-27),
4. 9783543 - Aminoimidazopyridazines (2017-10-10),
5. 9777004 - Amino-substituted imidazopyridazines (2017-10-03),
6. 9745304 - Amidoimidazopyridazines as MKNK-1 kinase inhibitors (2017-08-29),
7. 9643974 - Amino-substituted imidazopyridazines (2017-05-09),
8. 9604989 - Imidazopyridazines as Akt kinase inhibitors (2017-03-28),
9. 9540392 - Thienopyrimidines (2017-01-10),
10. 9409889 - Amino-substituted imidazopyridazines (2016-08-09),
11. 9382255 - Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors (2016-07-05),
12. 9370517 - Substituted pyrazolopyrimidines as Akt kinase inhibitors (2016-06-21),
13. 9260435 - Substituted imidazopyrazines as Akt kinase inhibitors (2016-02-16),
14. 9206185 - Imidazopyridazines as Akt kinase inhibitors (2015-12-08),
15. 8987286 - Substituted pyrimido[1,2-b]indazoles and their use as modulators of the Pi3K/Akt pathway (2015-03-24),

**Title: Andrea Hägebarth: Innovator in Pharmaceutical Patents**

Introduction

Andrea Hägebarth is a prominent inventor based in Berlin, Germany, known for his significant contributions to the field of pharmaceuticals. With a total of 18 patents to his name, Hägebarth has made notable advancements, particularly in the treatment of diseases such as cancer through innovative chemical compounds and combinations.

Latest Patents

Among his latest patented inventions, Hägebarth has developed compounds that relate to substituted N-(phenyl-heteroaryl)-3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-phenyl-heteroaryl-carboxamides. These compounds are designed to be useful in preparing pharmaceutical compositions for the treatment and prevention of diseases, including cancer. The general formula and details of these compounds reflect their complexity and potential impact on cancer treatment.

In addition, Hägebarth has patented a combination of PI3K inhibitors, comprising two components: one being an inhibitor of the PI3K kinase and the other a pharmaceutically acceptable salt of radium 223. This combination aims to enhance treatment options for patients with cancer that has metastasized to the bones.

Career Highlights

Throughout his career, Hägebarth has worked with reputable organizations, notably at Bayer Intellectual Property GmbH and Bayer Pharma Aktiengesellschaft. His tenure at these companies has been marked by a focus on innovation and the development of new therapeutic agents.

Collaborations

Hägebarth's work has also led to fruitful collaborations with noteworthy professionals, including Ulf Bömer and William Johnston Scott. These partnerships have fostered the development and refinement of his innovative ideas, further contributing to his success in the pharmaceutical industry.

Conclusion

In conclusion, Andrea Hägebarth exemplifies the spirit of innovation in the pharmaceutical sector. His extensive portfolio of patents demonstrates his commitment to advancing medical science, especially in cancer treatment. As a leading inventor, Hägebarth continues to influence the future of pharmaceuticals with his pioneering work and collaborative efforts.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…